Tregs and miRNAs in Breast Milk: Effects on Infant Food Tolerance
Immunoregulatory Factors in Human Breast Milk: Relationship Between Regulatory T Cells (Tregs), miRNAs and Food Tolerance
Study Overview
Status
Conditions
Detailed Description
Breast milk contains microRNAs (miRNAs) that contribute to the maturation of the infant immune system by influencing immune cell development, inflammatory mediator secretion, and maintenance of immunological homeostasis. Certain miRNAs, such as miR-92 and miR-17, play a role in B- and T-cell maturation, while miRNA-10a is associated with regulatory T cells (Tregs), which can modulate food allergic responses. This study aims to identify immunoregulatory Treg-associated miRNAs in breast milk, particularly those involved in the development and function of Treg cells; to analyze their expression in colostrum, transitional milk, and mature breast milk; to investigate their effects on Treg cells; and to examine the relationship between food tolerance and miRNA-Treg interactions.
Laboratory analyses will be conducted on maternal breast milk and infant blood samples. Breast milk samples will be manually expressed between 09:00 and 14:00 into sterile collection containers, with 7-10 mL collected per session. Five milliliters of each sample will be transferred into Eppendorf tubes and transported on ice within 30 minutes for molecular analysis. Each sample will be aliquoted into sterile 2 mL cryotubes, flash-frozen, and stored at -80°C until RNA isolation. The remaining 2-5 mL of each breast milk sample will be transported on ice within 30 minutes for immunologic and cytometric analyses. Infant blood samples obtained during routine follow-up visits will be analyzed for Treg-associated miRNAs and their target gene expression to evaluate correlations with maternal breast milk miRNA profiles and infant immune tolerance.
All laboratory analyses will be conducted using standard equipment and procedures in certified Genetics and Immunology laboratories. Through this approach, the study will examine longitudinal changes in Treg-associated miRNAs in breast milk, their correlation with infant immune parameters, and their potential role in promoting immune tolerance and preventing food allergy development. The results are expected to provide insights into early-life immune programming and may inform novel therapeutic interventions and preventive strategies.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Gonca Keskindemirci, MD, PhD
- Phone Number: 0905324934651
- Email: keskindemirci@hotmail.com
Study Locations
-
-
-
Istanbul, Turkey (Türkiye)
- Recruiting
- Child Health and Diseases Clinic, Esencan Hospital
-
Contact:
- Özden Durmuş Gönültaş, MD
- Phone Number: 905073121218
- Email: ozdengnlts@gmail.com
-
Sub-Investigator:
- Özden Durmuş Gönültaş, MD
-
Istanbul, Turkey (Türkiye)
- Recruiting
- İstanbul University İstanbul Medical Faculty Department of Pediatrics Division of Social Pediatrics
-
Contact:
- Gonca Keskindemirci, MD, PhD
- Phone Number: 0905324934651
- Email: keskindemirci@hotmail.com
-
Sub-Investigator:
- Özden Durmuş Gönültaş, MD
-
Principal Investigator:
- Gonca Keskindemirci, Prof
-
Principal Investigator:
- Gülbin E Gökçay, Prof
-
Principal Investigator:
- Günnur Deniz, Prof
-
Principal Investigator:
- Asuman Gedikbaşı, Prof
-
Principal Investigator:
- Birsen Karaman, Prof
-
Principal Investigator:
- Bilge Ş Selçuk, Assoc Prof
-
Sub-Investigator:
- Gizem Kara Elitok, Assoc Prof
-
Sub-Investigator:
- Ebru Kılıç
-
Sub-Investigator:
- Ayşenur Kökoğlu
-
Sub-Investigator:
- Suzin Tatonyan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Lactating mothers and their infants attending the Child Health and Diseases Clinic at Istanbul University Faculty of Medicine, or the Child Health and Diseases Clinic at Esencan Hospital.
- Infants who are exclusively breastfed for the first 6 months.
- Mothers willing to provide breast milk samples at multiple time points (colostrum, transitional milk, and mature milk at 1, 4, 6, and/or 9 months postpartum).
- Infants aged 0-9 months, born at term (≥37 weeks gestation) with no major congenital anomalies or chronic illnesses.
- Mothers and infants who provide informed consent for participation in the study.
Exclusion Criteria:
- Infants who are not exclusively breastfed for the first 6 months.
- Infants with chronic illnesses or diagnosed immunodeficiency, metabolic, or gastrointestinal disorders.
- Mothers who are unable or unwilling to provide informed consent.
- Mothers with chronic illnesses or immunological disorders that may affect breast milk composition.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Expression Levels of Treg-Associated miRNAs in Breast Milk
Time Frame: Colostrum (day 0-7), days 10-15 (transitional milk), and at 1, 4, 6, and 9 months postpartum
|
Quantitative analysis of regulatory T cell (Treg)-associated microRNA (miRNA) expression levels in breast milk samples.
|
Colostrum (day 0-7), days 10-15 (transitional milk), and at 1, 4, 6, and 9 months postpartum
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- TSA-2025-41296
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.